Research programme: haemophilia A stem cell therapy - Opus Bio

Drug Profile

Research programme: haemophilia A stem cell therapy - Opus Bio

Alternative Names: LG 889

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lentigen Corporation
  • Developer Expression Therapeutics; Opus Bio
  • Class Stem cell therapies
  • Mechanism of Action Blood coagulation factor replacements; Cell replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haemophilia A

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Haemophilia-A in USA (IV, Infusion)
  • 30 Dec 2014 9167038, 9167065 - corrected organisational relationships; changed owner to opus bio.
  • 14 Aug 2014 Lentigen Corporation starts operating as Opus Bio and gains certain rights to use lentiviral technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top